We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > EMD Serono

News List

EMD Serono Initiates Trial of TLR7, 8 Inhibitor as a Potential Treatment for Symptoms of Covid-19 americanpharmaceuticalreview
July 03, 2020
EMD Serono announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application (IND) for M5049 for the treatment of patients with Covid-19 pneumonia.
EMD Serono, Pfizer Receive Breakthrough Therapy Designation, Submit Application for BAVENCIO americanpharmaceuticalreview
April 15, 2020
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer announced completion of the submission.
Nebula Genomics Signs Agreement for Pilot Project with EMD Serono firstwordpharma
June 12, 2019
Nebula Genomics, which operates a technology platform containing genome-sequencing data, has signed an agreement with EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, for EMD Serono to access genomic dat
Smith Joins EMD Serono as Senior Vice President and Head of US Fertility and Endocrinology americanpharmaceuticalreview
January 18, 2017
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced that Richard R. Smith has joined the company as Senior Vice President and Head of US Fertility and Endocrinology.